Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Frank Ahfat"'
Autor:
Randhir Chavan, S J Aldington, Arevik Ghulakhszian, Roxanne Crosby-Nwaobi, Richard D. Smith, Priya Prakash, Edward Hughes, Geoffrey B. Arden, Debendra N. Sahu, Sarah Walker, Alaistair Denniston, Jackie Sturt, Nirodhini Narendran, Nisha Shah, Abosede Cole, Sobha Sivaprasad, Haralabos Eleftheriadis, Joanna Kelly, Peter H Scanlon, Afsar Jafree, Sheena George, Tatiana Mansour, S Chave, A Dale, Tunde Peto, Namritha Patrao, A Toby Prevost, Ajay Bhatnagar, Joana C. Vasconcelos, Philip Hykin, Douglas Lewin, Gary S. Rubin, Chris Hogg, Caroline Murphy, Gilli Vafidis, Maria Sandinha, Frank Ahfat, Geeta Menon, David P. Crabb, Catherine A Egan, Gillian Hood, Joanathan Gibson, Graham A. Hitman, Ian Grierson, Helen Holmes, Deepthy Menon, Lauren Leitch-Devlin
Publikováno v:
Sivaprasad, S, Vasconcelos, J C, Prevost, A T, Holmes, H, Hykin, P, George, S, Murphy, C, Kelly, J, Arden, G B, CLEOPATRA Study Group & Peto, T 2018, ' Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial ', The lancet. Diabetes & endocrinology . https://doi.org/10.1016/S2213-8587(18)30036-6
The Lancet. Diabetes & Endocrinology
The Lancet. Diabetes & Endocrinology
BACKGROUND: We aimed to assess 24-month outcomes of wearing an organic light-emitting sleep mask as an intervention to treat and prevent progression of non-central diabetic macular oedema.METHODS: CLEOPATRA was a phase 3, single-blind, parallel-group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da900962587753965c9a5f4b04bd3ca1
http://hdl.handle.net/10044/1/71846
http://hdl.handle.net/10044/1/71846
Autor:
Frank Ahfat
Publikováno v:
BMJ. 349:g7522-g7522
Lotery and MacEwen report that a switch from ranibizumab to bevacizumab for macular degeneration and other retinal disorders could save the NHS £102m (€129m; $160m) annually.1 In 2012, the IVAN study group suggested annual savings of £84m from su